[Course of Duchenne muscular dystrophy and its treatment].
The results of a 12 month follow-up of 3 groups of age-matched children (7 boys in each group) with an identically malignant course of Duchenne's myodystrophy determined by means of a genealogical analysis are presented. The fastest progression of the disease was observed in children receiving conventional treatment. Untreated children showed slower progression of the disease. In patients on allopurinol treatment the process was somewhat checked or there was some regression of symptomatology.
D000493:Allopurinol / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008696:Methandrostenolone / Q000627:therapeutic use; D009136:Muscular Dystrophies / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D009277:Nandrolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077603:Nandrolone Decanoate; D009388:Neostigmine / Q000627:therapeutic use; D013577:Syndrome; D014815:Vitamins / Q000627:therapeutic use
D014815:Vitamins; D009388:Neostigmine; D000493:Allopurinol; D009277:Nandrolone; D008696:Methandrostenolone; D000077603:Nandrolone Decanoate
O techenii miodistrofii Diushenna i ee terapii.